|Day Low/High||64.98 / 66.36|
|52 Wk Low/High||53.63 / 71.70|
A closer look at the fund's composition leads to a few head-scratchers, but most of the names seem to fairly represent its focus.
I haven't mentioned FibroGen in a few weeks - I have been adding on any dip. This is an important finding that Roxa improves left ventricle function of the heart where Epo does not. I suspect the FDA has given FGEN a path forward on Rica. It all c...
Even today's earnings beat is not 'moving the needle' enough.
But broadening patterns can be tricky to trade.
The Japanese equity market has underperformed this year but looks set to star in 2022. Watch these 10 stocks for strong tech- and Covid-linked gains.
Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.
I wouldn't expect a lot in the way of economic shutdowns, at least not unless clear evidence presents that people are getting sicker from Omicron.
* Back to adcom and FibroGen FGEN, this paper was published in August, 2021 showing that Roxadustat itself does not cause thrombosis, which again, if FDA is fair this time, they will know it wasn't the drug it was the dosage. * One of the main point...
* Where is the $100 million of extra cash coming into the company's coffers from between now and year-end? As I discussed in my thesis, FibroGen has done a great job of right sizing the company and preserving cash as it finances its drug research ...
Plus, the intersection of rising inflation and a slowing velocity of money give us reason for pause.
* I have begun to add to my holdings based on the company "right sizing" its operations FibroGen is a very speculative and development stage biotech company. Its main product is Roxadustat which treats anemia associated with chronic kidney disease...
Let's see how the charts are shaping up ahead of the numbers Friday.
With earnings season starting in earnest Wednesday, both indexes have offered investors nothing but lower highs coupled with lower lows since the start of September.
Watch Medigen stock, as the Taiwanese president becomes one of the first citizens of the island nation to roll up her sleeve.
Are traders and investors confused? Possibly. Was that the intent? No, but I think Jerome Powell is fine with that.
Just as fears of Fed tightening and a trade war created buying opportunities in tech and elsewhere in late 2018, arguably overblown fears about the Delta variant's economic impact are creating opportunities now.
Those rattles you hear on the COVID, Fed and political fronts are reasons to tread carefully in the markets.
The public seems to have resigned itself to dealing with a greater degree of inflation for longer than anything I would have considered to be 'transitory.' The again, the public is often as wrong as the Fed.
I prefer the bear put spread over the covered equity play due to the decreased risk to principal, despite the capped potential for profit.
This drugmaker is making a historic upside breakout. Let's check the charts.
Debt-free and poised to gain from its COVID-19 vaccine demand, MRNA could inject some life into your investment plan.
UPS and FDX are both in serious rally mode, yet in very different places in terms of technical development.
Plus, ServiceNow is a stock worth stalking and Amazon is a stock worth celebrating.
So far, for the season, the blended rate of earnings growth for the first quarter now stands at an incredible 33.8%.
Don't forget, this is a very large company with a lot more than the vaccine going on.
The AZN affair exposes the seedy underbelly of drug manufacturing, and the COVID-19 vaccine is certainly a drug.
Lies, damn lies, and statistics in the vaccine age, as Hong Kong and Macau stop administering the Pfizer/BioNTech drug.
Ever think you would see the day when all cash was digital so the federal government could place a negative interest rate (tax) on savings? I can see this coming from a mile away.
Here's my view on this space and where the money is to be made.
COVID numbers stopped improving a while ago, even with ever-improving rates of vaccination. Just what is going on here?